Nanostart AG, founded in 2003 and headquartered in Frankfurt, Germany, is a nanotechnology investment company focused on accelerating the commercialization and growth of emerging companies with nanotechnology-based products and processes. It targets industries such as cleantech and energy, life sciences, medicine and healthcare, and IT and electronics, typically investing between one and ten million euros directly or through a fund, and providing support in management, commercialization and access to capital markets.
At the time of the report Nanostart was invested in ten portfolio companies in Germany, Singapore and the United States, including a majority stake in MagForce Nanotechnologies AG, which had received EU approval for its NanoCancer therapy. Through its subsidiary Nanostart Asia Pte Ltd and the Nanostart Singapore Early Stage Venture Fund I, it was an investment partner of the Singapore government’s National Research Foundation. Its portfolio companies had completed five IPOs and two trade sales, most recently to Roche.
Frankfurt: NNS · Nanotechnology investing